Exploring T Cells as a Promising Therapeutic Target in Axial Spondyloarthritis
-
By
-
Mansi K. Aparnathi
-
Nigil Haroon
-
May 25, 2026
Clinical Report: Exploring T Cells as a Promising Therapeutic Target in Axial Spondyloarthritis
Background
Axial spondyloarthritis is a chronic inflammatory disease that significantly impacts patients' quality of life due to persistent back pain and potential spinal fusion. Current treatments primarily focus on symptom management, with a notable percentage of patients failing to respond to first-line biologic therapies. Understanding the role of T cells in axSpA is critical for further research.
Data Highlights
No numerical data available in the source material.
Key Findings
- axSpA is characterized by significant back pain and may involve extra-articular manifestations.
- 80% to 90% of axSpA patients carry the HLA-B27 gene.
- CD8+ T cells produce proinflammatory cytokines such as TNFα, IFNγ, and IL-17.
- T-bet expression levels in CD8+ T cells are higher in axSpA patients compared to healthy controls.
- 40% to 65% of axSpA patients do not respond to their first biologic therapy.
Clinical Implications
The involvement of T cells in axSpA pathogenesis is noted, but further research is needed to explore potential therapeutic targeting.
Conclusion
Further investigation into the role of T cells in axial spondyloarthritis is warranted.
Related Resources & Content
- American College of Rheumatology, Guideline Position, 2026 -- Axial Spondyloarthritis Guidelines
- Aparnathi, Arthritis & Rheumatology, 2023 -- T cells, the Next Big Target in Axial Spondyloarthritis?
- the medicine maker — CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis
- Frontiers in Immunology — Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs
- Journal of Crohn's and Colitis — Chimeric Antigen Receptor Tregs Targeting IL-23R in Crohn’s Disease: The Emergence of a New Era in Cellular Immunotherapy?
- Clinical Rheumatology — Abatacept: A Modulator of T-cell Co-stimulation for Managing Rheumatoid Arthritis
- CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis
- Targeting the synovial engine: next-generation engineered immune cells
- Chimeric Antigen Receptor Tregs Targeting IL-23R in Crohn’s Disease
- https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt424f1e71604af245/axspa-guideline-summary-2026.pdf
- Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - PubMed
- T cells, the Next Big Target in Axial Spondyloarthritis? - Aparnathi - Arthritis & Rheumatology - Wiley Online Library
Based on findings from:
T cells, the Next Big Target in Axial Spondyloarthritis?
Mansi K. Aparnathi, Nigil Haroon. Arthritis & Rheumatology, 2026.
https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70221
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
